Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22572956 | 0.92 | ALDH1A1 (0.34) | GPR35TXNRD1SMN1; SMN2LMNAMAPT | |
| SCHEMBL4539279 | 0.89 | MAPT (0.38) | TXNRD1LMNAMAPTCYP1A2ALDH1A1 | |
| SCHEMBL22089936 | 0.88 | JAK2 (0.34) | TXNRD1LMNAALDH1A1TDP1 | |
| SCHEMBL22572955 | 0.83 | MAPT (0.33) | GPR35TXNRD1MAPTMEN1KMT2A | |
| SCHEMBL28899995 | 0.83 | TXNRD1 (0.34) | TXNRD1MAPTCYP1A2MEN1KMT2A | |
| SCHEMBL22090173 | 0.77 | TXNRD1 (0.36) | TXNRD1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL24791181 | 0.72 | JAK2 (0.36) | GPR35TXNRD1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2551773 | 0.71 | GAA (0.34) | GPR35TXNRD1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL22749598 | 0.70 | — | — | |
| SCHEMBL43356 | 0.70 | GPR35 (0.38) | GPR35SMN1; SMN2LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264959-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AS PHOSPHOINOSIDIDE KINASE (PIK) MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-4635570-A2 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4620959-A1 | CYCLIC COMPOUNDS USED AS MULTI-TARGET KINASE INHIBITORS AND PREPARATION METHOD THEREFOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2025-09-24 | — | — | EP | disclosed |
| US-12358896-B2 | LRRK2 inhibitors and methods of making and using thereof | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-3998261-B1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4525875-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250034119-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2025-01-30 | — | — | US | disclosed |
| EP-2760857-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-06 | — | — | EP | disclosed |
| CN-103313978-A | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | disclosed |
| EP-2638031-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| EP-2556066-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-02-13 | — | — | EP | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011124580-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | GPR35 4376/4885TXNRD1 2264/4885SMN1; SMN2 3817/4885 |
| US-20250034119-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | GPR35 2101/4885TXNRD1 776/4885SMN1; SMN2 72/4885 |
| US-12358896-B2 | LRRK2 inhibitors and methods of making and using thereof | LRRK2, PARK7, GSK3B | GPR35 3352/4885TXNRD1 802/4885SMN1; SMN2 174/4885 |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | GPR35 263/4885TXNRD1 638/4885SMN1; SMN2 778/4885 |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | GPR35 2356/4885TXNRD1 2517/4885SMN1; SMN2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.